Patent · US Active

Immunoconjugates targeting syndecan-1 expressing cells and use thereof

US8840898B2 · kind B2 · utility

3Cited by

61References

10Claims

0Family size

Assignees

Biotest AG · DE
IMMUNOGEN, INC. · US

Inventor

Viktor S. Goldmakher · Newton, US

Key dates

Filing date	Apr 16, 2007
Grant date	Sep 23, 2014
Priority date	—
Expiry date	Feb 17, 2030

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Immunoconjugates comprising a targeting agent selectively targeting cell-surface expressed syndecan-1 and at least one effector molecule as well as in vitro and in vivo methods of using those immunocomjugates are disclosed. The effector molecule may have, in its native form, high non-selective cytotoxicity, but substantially no non-selective cytotoxicity when part of said immunoconjugate. Targeting agents include the antibody B-B4 as well as other agents that bind cell-surface expressed syndecan-1.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.